Health and Healthcare
Major Biotech Short Interest Continues to Be Mixed
Published:
Last Updated:
The short interest data are out for the January 29 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can make or break them. A single failed clinical trial can mean disaster for a stock. 24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies.
The January 29 short interest data have been compared with the previous report, and short interest was mixed in most of these selected stocks for this settlement date.
Amgen Inc. (NASDAQ: AMGN) saw its short interest rise to 10.41 million shares from the previous level of 9.03 million. Shares closed most recently at $143.16, in a 52-week trading range of $130.09 to $181.81.
Biogen Inc. (NASDAQ: BIIB) had its short interest decrease slightly to 2.76 million from the previous level of 2.85 million. Shares closed Tuesday at $249.99, within a 52-week range of $243.85 to $480.18.
Celgene Corp. (NASDAQ: CELG) short interest for this settlement date increased to 10.50 million shares from the previous 9.06 million. Shares of Celgene closed most recently at $100.50, in a 52-week range of $92.98 to $140.72.
Gilead Sciences Inc. (NASDAQ: GILD) saw its short interest fall to 21.37 million shares from 23.16 million in the previous period. Shares closed Tuesday at $87.25, in a 52-week trading range of $81.89 to $123.37.
MannKind Corp. (NASDAQ: MNKD) saw its short interest increase to 124.41 million shares. The previous reading was 123.89 million. Shares closed most recently at $0.97, in a 52-week trading range of $0.64 to $7.88.
Alexion Pharmaceuticals Inc. (NASDAQ: ALXN) short interest decreased to 5.47 million, compared to the
previous level of 5.65 million. Shares closed most recently at $136.46, in a 52-week range of $130.51 to $208.88.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
